PT  - JOURNAL ARTICLE
AU  - Matthew C. Woodruff
AU  - Richard P. Ramonell
AU  - Ankur Singh Saini
AU  - Natalie S. Haddad
AU  - Fabliha A. Anam
AU  - Mark E. Rudolph
AU  - Regina Bugrovsky
AU  - Jennifer Hom
AU  - Kevin S. Cashman
AU  - Doan C. Nguyen
AU  - Shuya Kyu
AU  - Michael Piazza
AU  - Christopher M. Tipton
AU  - Scott A. Jenks
AU  - F. Eun-Hyung Lee
AU  - Ignacio Sanz
TI  - Relaxed peripheral tolerance drives broad <em>de novo</em> autoreactivity in severe COVID-19
AID  - 10.1101/2020.10.21.20216192
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.10.21.20216192
4099  - http://medrxiv.org/content/early/2021/07/27/2020.10.21.20216192.short
4100  - http://medrxiv.org/content/early/2021/07/27/2020.10.21.20216192.full
AB  - An emerging feature of COVID-19 is the identification of autoreactivity in patients with severe disease that may contribute to disease pathology, however the origin and resolution of these responses remain unclear. Previously, we identified strong extrafollicular B cell activation as a shared immune response feature between both severe COVID-19 and patients with advanced rheumatic disease. In autoimmune settings, this pathway is associated with relaxed peripheral tolerance in the antibody secreting cell compartment and the generation of de novo autoreactive responses. Investigating these responses in COVID-19, we performed single-cell repertoire analysis on 7 patients with severe disease. In these patients, we identify the expansion of a low-mutation IgG1 fraction of the antibody secreting cell compartment that are not memory derived, display low levels of selective pressure, and are enriched for autoreactivity-prone IGHV4-34 expression. Within this compartment, we identify B cell lineages that display specificity to both SARS-CoV-2 and autoantigens, including pathogenic autoantibodies against glomerular basement membrane, and describe progressive, broad, clinically relevant autoreactivity within these patients correlated with disease severity. Importantly, we identify anti-carbamylated protein responses as a common hallmark and candidate biomarker of broken peripheral tolerance in severe COVID-19. Finally, we identify the contraction of this pathway upon recovery, and re-establishment of tolerance standards coupled with a concomitant loss of acute-derived ASCs irrespective of antigen specificity. In total, this study reveals the origins, breadth, and resolution of acute-phase autoreactivity in severe COVID-19, with significant implications in both early interventions and potential treatment of patients with post-COVID sequelae.Competing Interest StatementDr. Lee is the founder of MicroB-plex, Inc and has research grants with Genentech. Dr. Mark Rudolph is employed by Exagen, Inc. Dr. Michael Piazza is employed by Nicoya.Funding StatementThis work was supported by National Institutes of Health grants: UL TR000424 (Emory Library IT), U54-CA260563-01 Emory SeroNet (I.S., F.E.L.), U19-AI110483 Emory Autoimmunity Center of Excellence (I.S.), P01-AI125180-01 (I.S., F.E.L.), R37-AI049660 (I.S.), 1R01AI12125 (F.E.L.), 1U01AI141993 (F.E.L), T32-HL116271-07 (R.P.R.). Clinical autoreactivity testing was provided by Exagen, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All research was approved by the Emory University Institutional Review Board (Emory IRB numbers IRB00058507, IRB00057983, and IRB00058271) and was performed in accordance with all relevant guidelines and regulations. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRelevant data will be made available as necessary following peer-review